GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that, following good progress on obtaining clearances and approvals to enable completion of its three-part transaction with Novartis, it expects to complete the transaction in the week commencing 2 March 2015.
Originally announced on 22 April 2014, the transaction includes GSK’s acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed Oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.As GSK explained when the proposed transaction was announced in April last year, the three parts are:
- GSK and Novartis will create a new world-leading Consumer Healthcare business with 2013 pro forma revenues of £6.5 billion. GSK will have majority control with an equity interest of 63.5%
- GSK will acquire Novartis’ global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion with subsequent potential milestone payments of up to $1.8 billion and ongoing royalties
- GSK will divest its marketed Oncology portfolio, related R&D activities and rights to its AKT inhibitor and also grant of commercialisation partner rights for future oncology products to Novartis for an aggregate cash consideration of $16 billion (of which up to $1.5 billion depends on the results of the COMBI-d trial)
As a result of this, GSK intends to return £4 billion to shareholders (via a B shares scheme). With the 4.86 billion share outstanding from the company this would be a capital return of about 82p per GSK share.
GSK is by far my largest holding. As a result, with my 191 shares I should expect to receive about £156 from this windfall. But what is more exciting is the nature of the three-part deal itself. Hopefully this will be helpful in streamlining operations and deriving stronger growth going forward.
You can read the original press release today here.
[Creative Commons image reproduced from Flickr user Ian Wilson (foolstopzanet)]
You can read the original press release today here.
[Creative Commons image reproduced from Flickr user Ian Wilson (foolstopzanet)]
Want to keep up to date with the Dividend Drive? You can subscribe by email or follow me on Twitter.
No comments:
Post a Comment